Information on the target
HCAP Partners has recently invested in PACIV, a prominent full-service provider of industrial automation solutions based in San Juan, Puerto Rico. Established in 1997, PACIV has positioned itself as a trusted partner in the process automation landscape, offering a comprehensive suite of services that includes instrumentation, control systems, and regulatory compliance tailored for the biotechnology, pharmaceutical, medical device, and related industries. With a workforce of 120 employees across three offices, PACIV is recognized as the largest systems integrator in Puerto Rico and one of the largest in the Midwest.
This investment is part of a co-investment strategy with Blackford Capital, which announced its acquisition of PACIV earlier this month. The financial terms of the investment have not been disclosed, but the capital infusion is intended to support PACIV's expansion plans, enabling the company to accelerate growth and enhance its service offerings in the rapidly evolving industrial automation sector.
Industry overview in the target’s specific country
The Environmental R&D Services & Biotechnology industry in Puerto Rico plays a critical role in the global biotechnology landscape, particularly given the island's strategic position as a hub for pharmaceutical and biopharmaceutical manufacturing. The industry benefits from a robust infrastructure, a skilled workforce, and favorable tax incentives that attract significant investment from multinational corporations. Puerto Rico's biotechnology sector is characterized by a strong emphasis on research and development, with numerous companies engaged in innovative projects aimed at improving health outcomes and environmental sustainability.
In recent years, the Puerto Rican government has implemented various initiatives to bolster the biotechnology industry, including funding for research institutions and partnerships with private firms. This has led to an increase in the number of biotech startups and a growing ecosystem that supports innovation. The focus on environmental sustainability has also driven demand for R&D services that address regulatory compliance and environmental impact, further enhancing the industry's growth potential.
Moreover, the COVID-19 pandemic has underscored the importance of biotechnology in public health, leading to increased funding and interest in the sector. Companies in Puerto Rico are leveraging advanced technologies and methodologies to develop new therapies and vaccines, positioning themselves as leaders in the global market. The convergence of biotechnology and environmental R&D services is expected to create new opportunities for companies like PACIV, which provide essential automation solutions that facilitate efficient and compliant manufacturing processes.
The rationale behind the deal The investment in PACIV aligns with HCAP Partners' strategy to deploy capital in underserved markets that have the potential for significant job growth and economic impact. PACIV's established reputation and deep industry knowledge make it an ideal candidate f…